☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Inegy cancer concerns

The Food and Drugs Administration (FDA) has announced that it is investigating data from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study that found an increased rate of cancer. The media have reported this announcement (Daily Express).

The SEAS Study recruited approximately 1,400 patients with aortic stenosis. Participants were randomised to treatment with simvastatin 40mg and ezetimibe 10mg daily or placebo. The primary outcome for the study was a composite of major cardiovascular endpoints including valve replacements, heart failure and cardiovascular death.

The study found no difference in the primary outcome despite a 61% reduction in low-density lipoprotein cholesterol (LDL-C). There were more adverse events related to cancer in the treatment arm of the study (93 [9.9%] versus 65 [7.0%], p=0.03) and more cancer related deaths (39 [4.1%] versus 23 [2.5%], p=0.05).

These findings are based on small numbers from a single study. Additionally, the FDA note that large prospective studies have not demonstrated any increase in cancer incidence in treatment arms compared to placebo. The FDA investigation is on-going and is likely to report final recommendations early in 2009, in the meantime they recommend that patients continue taking cholesterol lowering medication and consult their doctor if they have concerns.

Action: Patients should be reassured and advised to continue taking cholesterol lowering medication. Healthcare professionals should continue to report any suspected side effects.

Share 'Inegy cancer concerns' by emailShare 'Inegy cancer concerns' on FacebookShare 'Inegy cancer concerns' on TwitterShare 'Inegy cancer concerns' on MastodonShare 'Inegy cancer concerns' on LinkedInShare 'Inegy cancer concerns' on reddit

atomic-wealth

5 Comments to “Inegy cancer concerns”

  1. [...] in 2008, troubling study findings were released showing a dramatically increased risk of cancer related deaths in those taking Inegy (also sold under the trade name Vytorin). The drug combines the widely-used statin drug simvastatin [...]

    Pingback by Statins, Cancer & Cholesterol – Legitimate doubts about mainstream medications | The GOLDEN RULE — September 27, 2012 #
    Reply

  2. [...] in 2008, troubling study findings were released showing a dramatically increased risk of cancer related deaths in those taking Inegy (also sold under the trade name Vytorin). The drug combines the widely-used statin drug simvastatin [...]

    Pingback by Statin Drugs May Increase Your Prostate Cancer Risk | Health Impact News — December 8, 2011 #
    Reply

  3. [...] Link Back in 2008, troubling study findings were released showing a dramatically increased risk of cancer related deaths in those taking Inegy (also sold under the trade name Vytorin). The drug combines the widely-used statin drug simvastatin [...]

    Pingback by The Cancer-Causing Mistake 1 in 4 People Over 45 Make | Next Level Nutrition — December 8, 2011 #
    Reply

  4. [...] in 2008, troubling study findings were released showing a dramatically increased risk of cancer related deaths in those taking Inegy (also sold under the trade name Vytorin). The drug combines the widely-used statin drug simvastatin [...]

    Pingback by The Cancer-Causing Mistake 1 in 4 People Over 45 Make - The Healthy Life Tips — December 7, 2011 #
    Reply

  5. I WAS TAKING INEGY 10 MG TO LOWER MY CHOLESTROL FOR A PERIOD OF 3 YEARS AND I DEVELOPED CARCINOMA OF THE LOWER TONGUE I HAVE SUFFERED TREMENDOUS STRESS AND TRAUMA SINCE THEN. I WAS OPERATED AND THE AFFECTED AREA OF THE TONGUE WAS SURGICALLY REMOVED. AM LOVING IN CONSTANT FEAR AND UNCERTANITY

    Comment by SHIVARAM — April 18, 2009 #
    Reply

Leave a Reply to Statin Drugs May Increase Your Prostate Cancer Risk | Health Impact News Cancel reply

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.